AKT-mTOR/P53 PathwayDriven RapamycinAlpelisib Efficacy in Animal Models of TIE2Mutant Venous Malformations
Frontiers in Bioscience-Landmark · 01.06.2026 · 31 (6)
DOI: 10.31083/fbl48694 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Bioscience-Landmark, online erschienen am 01.06.2026. Verfasst von Yi Li und 5 weiteren Autor:innen. Beteiligte Einrichtung: 920th Hospital of Joint Logistics Support Force, PLA, 650032 Kunming, Yunnan, China. Hauptthemen laut MEDLINE: Tumor Suppressor Protein p53, TOR Serine-Threonine Kinases, Vascular Malformations, Receptor, TIE-2. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Yunnan Provincial Science and Technology Talent and Platform Planning Project, Xingdian Talents Program Famous Medical Specialty Project.
Abstract (Originalsprache)
Background
Sporadic venous malformations are a prevalent vascular anomaly in the oral and maxillofacial region. Current therapeutic strategies are associated with high recurrence rates and limited applicability in critical anatomical regions. Therefore, there is a pressing demand for more effective treatment modalities to address these challenges.
Methods
This study utilized transcriptome sequencing to analyze samples from venous malformation patients and combined lesion tissue analysis, cell culture, and xenograft mouse models to investigate the pathogenic mechanisms and potential therapeutic approaches for venous malformations.
Results
Our findings indicated that the primary pathological features of venous malformations include abnormal angiogenesis and excessive activation of the phosphoinositide 3-kinase (PI3K) signaling pathway. In endothelial cells with the most common pathogenic mutation, TIE2-L914F, this mutation activates the PI3K pathway, promoting cell proliferation, inhibiting normal angiogenesis, and suppressing apoptosis. Treatment with PI3K inhibitors effectively reversed these pathological changes. More importantly, the combination of rapamycin and alpelisib exhibited superior therapeutic efficacy, not only significantly inhibiting the PI3K pathway but also activating P53 expression, thereby effectively preventing disease progression. Further validation through in vitro 3D angiogenesis assays and xenograft mouse models confirmed the therapeutic potential of this combination. The results demonstrated a marked reduction in vessel sprouting in the 3D model and inhibited both lesion size and angiogenesis in the xenograft mouse model.
Conclusions
This study is the first to demonstrate that the combination of rapamycin and alpelisib, through multi-target synergy, effectively inhibits the PI3K pathway and activates P53 expression, offering new insights and therapeutic options for the treatment of venous malformations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- 920th Hospital of Joint Logistics Support Force, PLA, 650032 Kunming, Yunnan, China.
- Yunnan Key Laboratory of Stomatology, Kunming Medical University, 650500 Kunming, Yunnan, China.
- Department of Oral and Maxillofacial Surgery, The First People's Hospital of Yunnan Province, 650032 Kunming, Yunnan, China.
- Shiyan Key Laboratory of Comprehensive Prevention and Treatment of Oral Cancer, Department of Stomatology, Taihe Hospital, Hubei University of Medicine, 442000 Shiyan, Hubei, China.
- Institute of Oral Diseases, School of Dentistry, Hubei University of Medicine, 442000 Shiyan, Hubei, China.
Förderung
- Yunnan Provincial Science and Technology Talent and Platform Planning Project
- Xingdian Talents Program Famous Medical Specialty Project
Zitieren
APA
Li, Y., He, Y., Lin, J., Wang, T., Wang, W., & Tang, Z. (2026). AKT-mTOR/P53 PathwayDriven RapamycinAlpelisib Efficacy in Animal Models of TIE2Mutant Venous Malformations. Frontiers in Bioscience-Landmark, 31(6). https://doi.org/10.31083/fbl48694
Vancouver
Li Y, He Y, Lin J, Wang T, Wang W, Tang Z. AKT-mTOR/P53 PathwayDriven RapamycinAlpelisib Efficacy in Animal Models of TIE2Mutant Venous Malformations. Frontiers in Bioscience-Landmark. 2026;31(6). doi:10.31083/fbl48694
BibTeX
@article{Li2026,
author = {Li, Yi and He, Yang and Lin, Jian and Wang, Tong and Wang, Wei and Tang, Zhencun},
title = {AKT-mTOR/P53 PathwayDriven RapamycinAlpelisib Efficacy in Animal Models of TIE2Mutant Venous Malformations},
journal = {Frontiers in Bioscience-Landmark},
year = {2026},
volume = {31},
number = {6},
doi = {10.31083/fbl48694}
}
EUVIMED